N/A N=20 Wrist Arthroscopy Study
Wrist Arthropathy
Primary: Surgeon-Rated Radiocarpal Visualization With Arthrex Nanoscope — 4.95 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=440 The Insulin-Only Bionic Pancreas Pivotal Trial
Diabetes Mellitus · Type 1 Diabetes · Diabetes Mellitus, Type 1
Primary: HbA1c — 56; 54; 61 mmol/mol — p=<0.001
N/A N=1,656 Options for Delivering Isoniazid-Rifapentine (3HP) for TB Prevention (3HP Options Implementation Trial)
Tuberculosis · Latent Tuberculosis · HIV/AIDS
Primary: Proportion of Participants Who Accepted and Completed 3HP — 0.946; 0.922; 0.944 proportion of participants
N/A N=31 tDCS for Impulsivity and Compulsivity in Obesity
Impulsivity · Compulsive Overeating · Obesity
Primary: Change in NIH Examiner Flanker Task Reaction Time — -0.03; -0.12 seconds
N/A N=60 Prophylactic Maze to Prevent Atrial Fibrillation in Adult Cardiac Surgery
Coronary Artery Disease
Primary: Incidence of Documented Post-operative Atrial Fibrillation — 17; 2 Participants
N/A N=40 A Clinical Performance of Two Soft Toric Contact Lenses
Astigmatism
Primary: Subjective Overall Score — 71.6; 78.9 score on a scale
Phase 3 N=405 Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)
Infertility
Primary: Number of Fertilized (2 Pronuclei [2PN]) Oocytes — 8.3; 6.7 Fertilized oocytes
Phase 1 N=14 Study of Milademetan in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) Following Administration of Milademetan in Participants With Relapsed or Refractory Acute Myeloid Leukemia…
N/A N=994 Boston Scientific Post Market Subcutaneous-Implantable Cardioverter Defibrillator (S-ICD) Registry
Tachycardia, Ventricular
Primary: Perioperative S-ICD Complication Free Rate — 983 Participants
Phase 2 N=63 Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignancies
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive · Acute Erythroid Leukemia · Acute Megakaryoblastic Leukemia
Primary: Number of Participants Who Experienced Dose-limiting Toxicities (DLT) — 2; 1; 0; 0 Participants
Phase 2 N=86 GB002 in Adult Subjects With Pulmonary Arterial Hypertension (PAH)
Pulmonary Artery Hypertension
Primary: Change From Baseline to Week 24 in Pulmonary Vascular Resistance (PVR) — 21.2; -74.9 dyne•s/cm^5 — p=0.0310
N/A N=30 Pilot Study of the Safety and Efficacy of Apremilast in Subjects With Moderate to Severe Alopecia Areata
Alopecia Areata
Primary: Number of Patients With SALT50 — 1; 1 Participants
Phase 2 N=15 Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)
Juvenile Myelomonocytic Leukemia
Primary: Determine Probability of Long-term Disease Free Survival in JMML — 67 Percentage of participants
Phase 2 N=20 Stellate Ganglion Block for COVID-19-Induced Olfactory Dysfunction
Anosmia · Hyposmia · Parosmia
Primary: Clinical Global Impression - Improvement (CGI-I) Score — 12; 8; 0; 0 Participants
Phase 2 N=73 Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Sarcoma, Soft Tissue · Soft Tissue Sarcoma · Undifferentiated Pleomorphic Sarcoma
Primary: Progression-free Survival (PFS) (Arm 1 Only) — 5.48 months